QuidelOrtho (QDEL) Stock Price, News & Analysis

Company Overview

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $30.76 to $31.95
• 50-Day Range: $24.46 to $37.42
• 52-Week Range: $23.77 to $49.45
• Volume: 1.48 million shs
• Average Volume: 1.08 million shs
• Market Capitalization: $2.14 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $44.33
• Consensus Rating: Hold

QuidelOrtho Stock Analysis - MarketRank™

QuidelOrtho scored higher than 93% of companies evaluated by MarketBeat, and ranked 102nd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

QuidelOrtho has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 4 buy ratings, 2 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

QuidelOrtho has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 39.57%

Earnings Growth

Earnings for QuidelOrtho are expected to grow by 39.57% in the coming year, from $2.30 to $3.21 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of QuidelOrtho is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of QuidelOrtho is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

QuidelOrtho has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.35% of the float of QuidelOrtho has been sold short.

Short Interest Ratio / Days to Cover

QuidelOrtho has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in QuidelOrtho has recently decreased by 1.40%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

QuidelOrtho does not currently pay a dividend.

Dividend Growth

QuidelOrtho does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.8 / 5
• Environmental Score: -2.61

Percentage of Shares Shorted

6.35% of the float of QuidelOrtho has been sold short.

Short Interest Ratio / Days to Cover

QuidelOrtho has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in QuidelOrtho has recently decreased by 1.40%, indicating that investor sentiment is improving.

News and Social Media

• Score: 4.1 / 5
• News Sentiment: 1.36

News Sentiment

QuidelOrtho has a news sentiment score of 1.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for QuidelOrtho this week, compared to 7 articles on an average week.

Search Interest

11 people have searched for QDEL on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added QuidelOrtho to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, QuidelOrtho insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.79% of the stock of QuidelOrtho is held by insiders.

Percentage Held by Institutions

99.00% of the stock of QuidelOrtho is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

QDEL Stock Analysis - Frequently Asked Questions

How have QDEL shares performed this year?

QuidelOrtho's stock was trading at $44.55 on January 1st, 2025. Since then, QDEL shares have decreased by 28.8% and is now trading at $31.70.
View the best growth stocks for 2025 here.

How were QuidelOrtho's earnings last quarter?

QuidelOrtho Co. (NASDAQ:QDEL) released its quarterly earnings data on Wednesday, May, 7th. The company reported $0.74 EPS for the quarter, beating the consensus estimate of $0.61 by $0.13. QuidelOrtho's revenue was down 2.6% compared to the same quarter last year.
Read the conference call transcript.

Who are QuidelOrtho's major shareholders?

Top institutional investors of QuidelOrtho include T. Rowe Price Investment Management Inc. (16.97%), Vanguard Group Inc. (10.01%), Invesco Ltd. (5.65%) and AQR Capital Management LLC (3.94%). Insiders that own company stock include Brian J Blaser, Joseph M Busky and Carlyle Group Inc.
View institutional ownership trends.

How do I buy shares of QuidelOrtho?

Shares of QDEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of QuidelOrtho own?

Based on aggregate information from My MarketBeat watchlists, some other companies that QuidelOrtho investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), PayPal (PYPL), Salesforce (CRM) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 5/28/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Diagnostic substances
• Sub-Industry: Health Care Supplies
• Current Symbol: NASDAQ:QDEL
• CIK: 353569
• Web: www.quidel.com
• Phone: (800) 874-1517
• Fax: 858-453-4338
• Employees: 7,000
• Year Founded: 1979

Price Target and Rating

• Average Stock Price Target: $44.33
• High Stock Price Target: $61.00
• Low Stock Price Target: $25.00
• Potential Upside/Downside: +39.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.43
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($4.97)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 13.78
• P/E Growth: N/A
• Net Income: -$2.03 billion
• Net Margins: -72.84%
• Pretax Margin: -76.59%
• Return on Equity: 3.78%
• Return on Assets: 1.80%

Debt

• Debt-to-Equity Ratio: 0.71
• Current Ratio: 1.22
• Quick Ratio: 0.69

Sales & Book Value

• Annual Sales: $2.76 billion
• Price / Sales: 0.78
• Cash Flow: $24.57 per share
• Price / Cash Flow: 1.29
• Book Value: $44.75 per share
• Price / Book: 0.71

Miscellaneous

• Outstanding Shares: 67,626,000
• Free Float: 66,584,000
• Market Cap: $2.14 billion
• Optionable: Optionable
• Beta: 0.13